Takeda Pharmaceutical (TSE:4502) Margin Miss Reinforces Bearish Narratives After ¥250.7B One-Off Loss [Yahoo! Finance]
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) (TAK)
Company Research
Source: Yahoo! Finance
from 6.4% a year earlier, as a one-off loss of ¥250.7 billion weighed heavily on results. The company's earnings have slipped by an average of 16.1% per year over the past five years, and most recently, earnings growth remained negative. Although profit margins have come under pressure, investors are looking to the future with forecasts calling for a substantial 29.86% annual EPS growth over the next three years despite only modest annual revenue growth of 2.1%. See our full analysis for Takeda Pharmaceutical. With these numbers on the table, the next section puts Takeda's latest results head-to-head with key narratives in the investment community to see where expectations and outcomes converge or clash. See what the community is saying about Takeda Pharmaceutical TSE:4502 Revenue & Expenses Breakdown as at Nov 2025 Debt Burden Shadows Profit Margin Hopes Takeda's net profit margin sits at just 0.7% following a one-off loss of ¥250.7 billion, emphasizing the company's chal
Show less
Read more
Impact Snapshot
Event Time:
TAK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TAK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TAK alerts
High impacting Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) news events
Weekly update
A roundup of the hottest topics
TAK
News
- American Neurology Summit 2025 Achieves Major Success With Full Attendance and High EngagementPR Web
- Takeda Pharmaceutical (NYSE:TAK) had its "hold (c-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Takeda Pharmaceutical (NYSE:TAK) had its "hold (c-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Takeda Pharmaceutical (NYSE:TAK) had its "hold (c-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Takeda Pharmaceutical (TSE:4502): Assessing Valuation After Subtle Share Price Changes [Yahoo! Finance]Yahoo! Finance
TAK
Sec Filings
- 12/4/25 - Form 144
- 11/28/25 - Form 6-K
- 11/13/25 - Form 13F-HR
- TAK's page on the SEC website